Hariprasad Vankayalapati

Dr. Hariprasad Vankayalapati

Huntsman Cancer institute
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

31 July 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RSRaffaella Soldi
Raffaella Soldi
SHStephen K. Horrigan
Stephen K. Horrigan
MCMarek W. Cholody
Marek W. Cholody
JPJanak Padia
Janak Padia
VSVenkataswamy Sorna
Venkataswamy Sorna
SSSunil Sharma
Sunil Sharma

11 August 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
KAKristin A. Altwegg
Kristin A. Altwegg
SVSuryavathi Viswanadhapalli
Suryavathi Viswanadhapalli
MMMonica Mann
Monica Mann
Dimple ChakravartyDimple Chakravarty
Dimple Chakravarty
SKSamaya Krishnan
Samaya Krishnan
RVRatna Vadlamudi
Ratna Vadlamudi
Most patients with estrogen receptor alpha–positive (ER+) breast cancers initially respond to treatment but eventually develop therapy resistance with disease progression. Overexpression of oncogenic ER coregulators, including proline, glutamic acid, and leucine-rich protein 1 (PELP1), are implicated in breast cancer progression. The lack of small molecules that inhibits PELP1 represents a major knowledge gap. Here, using a yeast-two-hybrid screen, we identified novel peptide inhibitors of PELP1 (PIP). Biochemical assays demonstrated that one of these peptides, PIP1, directly interacted with PELP1 to block PELP1 oncogenic functions. Computational modeling of PIP1 revealed key residues contributing to its activity and facilitated the development of a small-molecule inhibitor of PELP1, SMIP34, and further analyses confirmed that SMIP34 directly bound to PELP1. In breast cancer cells, SMIP34 reduced cell growth in a dose-dependent manner. SMIP34 inhibited proliferation of not only wild-type (WT) but also mutant (MT) ER+ and therapy-resistant breast cancer cells, in part by inducing PELP1 degradation via the proteasome pathway. RNA sequencing analyses showed that SMIP34 treatment altered the expression of genes associated with estrogen response, cell cycle, and apoptosis pathways. In cell line–derived and patient-derived xenografts of both WT and MT ER+ breast cancer models, SMIP34 reduced proliferation and significantly suppressed tumor progression. Collectively, these results demonstrate SMIP34 as a first-in-class inhibitor of oncogenic PELP1 signaling in advanced breast cancer. Significance: Development of a novel inhibitor of oncogenic PELP1 provides potential therapeutic avenues for treating therapy-resistant, advanced ER+ breast cancer.

25 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DFDengxuan Fan
Dengxuan Fan
HYHailing Yang
Hailing Yang
WMWeiqun Mao
Weiqun Mao
PRPhilip J. Rask
Philip J. Rask
LPLan Pang
Lan Pang
ZLZhen Lu
Zhen Lu
Salt-induced kinase 2 (SIK2) is a serine-threonine kinase that regulates centrosome splitting, activation of PI3 kinase and phosphorylation of class IIa HDACs, affecting gene expression. Previously, we found that inhibition of SIK2 enhanced sensitivity of ovarian cancer cells to paclitaxel. Carboplatin and paclitaxel constitute first-line therapy for most patients with ovarian carcinoma, producing a 70% clinical response rate, but curing <20% of patients with advanced disease. We have asked whether inhibition of SIK2 with ARN-3261 enhances sensitivity to carboplatin in ovarian cancer cell lines and xenograft models. ARN-3261-induced DNA damage and apoptosis were measured with γ-H2AX accumulation, comet assays, and annexin V. ARN-3261 inhibited growth of eight ovarian cancer cell lines at an IC50 of 0.8 to 3.5 µM. ARN-3261 significantly enhanced sensitivity to carboplatin in seven of eight ovarian cancer cell lines and a carboplatin-resistant cell line tested. Furthermore, ARN-3261 in combination with carboplatin produced greater inhibition of tumor growth than carboplatin alone in SKOv3 and OVCAR8 ovarian cancer xenograft models. ARN-3261 enhanced DNA damage and apoptosis by downregulating expression of survivin. Thus, a SIK2 kinase inhibitor enhanced carboplatin-induced therapy in preclinical models of ovarian cancer and deserves further evaluation in clinical trials.

17 September 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
LMLingyao Meng
Lingyao Meng
KCKent Carpenter
Kent Carpenter
AMAlexis Mollard
Alexis Mollard
HVHariprasad Vankayalapati
Hariprasad Vankayalapati
SWSteven L. Warner
Steven L. Warner
DBDavid J. Bearss
David J. Bearss
Background. Nek2 is a serine/threonine kinase localized to the centrosome. It promotes cell cycle progression from G2 to M by inducing centrosome separation. Recent studies have shown that high Nek2 expression is correlated with drug resistance in multiple myeloma patients.Materials and Methods. To investigate the role of Nek2 in bortezomib resistance, we ectopically overexpressed Nek2 in several cancer cell lines, including multiple myeloma lines. Small-molecule inhibitors of Nek2 were discovered using an in-house library of compounds. We tested the inhibitors on proteasome and cell cycle activity in several cell lines.Results. Proteasome activity was elevated in Nek2-overexpressing cell lines. The Nek2 inhibitors inhibited proteasome activity in these cancer cell lines. Treatment with these inhibitors resulted in inhibition of proteasome-mediated degradation of several cell cycle regulators in HeLa cells, leaving them arrested in G2/M. Combining these Nek2 inhibitors with bortezomib increased the efficacy of bortezomib in decreasing proteasome activityin vitro. Treatment with these novel Nek2 inhibitors successfully mitigated drug resistance in bortezomib-resistant multiple myeloma.Conclusion. Nek2 plays a central role in proteasome-mediated cell cycle regulation and in conferring resistance to bortezomib in cancer cells. Taken together, our results introduce Nek2 as a therapeutic target in bortezomib-resistant multiple myeloma.

1 December 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
TCTing Chen
Ting Chen
VSVenkataswamy Sorna
Venkataswamy Sorna
SCSusie Choi
Susie Choi
LCLee Call
Lee Call
JBJared Bearss
Jared Bearss
HVHariprasad Vankayalapati
Hariprasad Vankayalapati